John Tavis | Professor of Molecular Microbiology and Immunology
St Louis University School Of Medicine

John Tavis, Professor of Molecular Microbiology and Immunology, St Louis University School Of Medicine

John Tavis, Ph.D., is a Professor of Molecular Virology at Saint Louis University and Director of the Saint Louis University Institute for Drug and Biotherapeutic Innovation. He received his doctorate in molecular virology from Penn State University in 1990 and did postdoctoral studies in molecular virology at the University of California – San Francisco. He is the Chairman of the Scientific Advisory Council for the annual International Molecular Biology of the Hepatitis B Viruses Meeting, Incoming Chair of the International Coalition to Eliminate HBV (ICE-HBV), and a member of the Scientific and Medical Advisory Board member for the Hepatitis B Foundation and Baruch S. Blumberg Institute. His work on controlling cancer led to receipt of the Mission Hero Award from the American Cancer Society in 2018. He has studied the HBV replication mechanism and the biochemistry of viral reverse transcription since 1992. His current work focuses on the basic biochemistry of the HBV ribonuclease H and developing drugs to suppress HBV replication that target this essential enzyme.


Day 2 - November 29 @ 12:50

Early development of novel anti-HBV ribonuclease H inhibitors

Day 2 - November 29 @ 16:30

Panel: Toward a Hepatitis B-Free Future: Perspectives on Achieving a Functional Cure

  • How do you define a functional / partial cure – how should we use these terms and what are their limitations?

  • Which technologies/ modalities are we using to achieve a functional cure? What are the limits of different approaches? Can they be combined for more therapeutic benefit? (Antivirals, Antibodies, Vaccines, siRNA

  • Components to an effective cure strategy:

    o Use of viral replication inhibitors

    o Reducing viral surface antigen load – do we still have room to further reduce load?

    o Activation of antiviral immune response

  • Challenges in balancing side-effects and therapeutic efficacy

    How do we manage / avoid resistance


last published: 02/Jan/24 12:15 GMT

back to speakers